Imaging Cognitive Impairment and Impulse Control Disorders in Parkinson's Disease

por Martín-Bastida, Antonio, Delgado-Alvarado, Manuel, Navalpotro-Gómez, Irene, Rodríguez-Oroz, María Cruz
Publicado 2021

Interactions between functional networks in Parkinson's disease mild cognitive impairment

por Delgado-Alvarado, Manuel, Ferrer-Gallardo, Vicente J., Paz-Alonso, Pedro M., Caballero-Gaudes, César, Rodríguez-Oroz, María C.
Publicado 2023

S173. GREY MATTER VOLUME DEFFICITS IN PATIENTS WITH A FIRST EPISODE NON-AFFECTIVE PSYCHOSIS AND SUICIDE RELATED BEHAVIOUR

por Tordesillas-Gutiérrez, Diana, Canal-Rivero, Manuel, Setien-Suero, Esther, Ayesa-Arriola, Rosa, Delgado-Alvarado, Manuel, Crespo-Facorro, Benedicto
Publicado 2018

Using Kinect to classify Parkinson’s disease stages related to severity of gait impairment

por Dranca, Lacramioara, de Abetxuko Ruiz de Mendarozketa, Lopez, Goñi, Alfredo, Illarramendi, Arantza, Navalpotro Gomez, Irene, Delgado Alvarado, Manuel, Cruz Rodríguez-Oroz, María
Publicado 2018

The right occipital lobe and poor insight in first-episode psychosis

por Tordesillas-Gutierrez, Diana, Ayesa-Arriola, Rosa, Delgado-Alvarado, Manuel, Robinson, Jennifer L., Lopez-Morinigo, Javier, Pujol, Jesus, Dominguez-Ballesteros, M. Encarnación, David, Anthony S., Crespo-Facorro, Benedicto
Publicado 2018

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

por Riancho, Javier, Setien, Sonia, Sánchez de la Torre, Jose Ramón, Torres-Barquin, Marta, Misiego, Mercedes, Pérez, José Luis, Castillo-Triviño, Tamara, Menéndez-García, Cristina, Delgado-Alvarado, Manuel
Publicado 2021

Neurogenetic traits outline vulnerability to cortical disruption in Parkinson’s disease

por Basaia, Silvia, Agosta, Federica, Diez, Ibai, Bueichekú, Elisenda, d'Oleire Uquillas, Federico, Delgado-Alvarado, Manuel, Caballero-Gaudes, César, Rodriguez-Oroz, MariCruz, Stojkovic, Tanja, Kostic, Vladimir S., Filippi, Massimo, Sepulcre, Jorge
Publicado 2022

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study

por Santiago-Setien, Pilar, Barquín-Rego, Cristina, Hernández-Martínez, Paula, Ezquerra-Marigomez, María, Torres-Barquin, Marta, Menéndez-Garcia, Cristina, Uriarte, Fernando, Jiménez-López, Yésica, Misiego, Mercedes, Sánchez de la Torre, Jose Ramón, Setien, Sonia, Delgado-Alvarado, Manuel, Riancho, Javier
Publicado 2023